[
  {
    "id": "glucagonoma-alpha-cell-tumors_27577_1750166973.txt-1",
    "source_document": "glucagonoma-alpha-cell-tumors_27577_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Definition / general",
    "url": "https://www.pathologyoutlines.com/topic/pancreasglucagonoma.html#definitiongeneral268955",
    "clean_content": "Definition / general\n\n* Rare, poorly characterized pancreatic neuroendocrine tumor that produces glucagon"
  },
  {
    "id": "glucagonoma-alpha-cell-tumors_27577_1750166973.txt-2",
    "source_document": "glucagonoma-alpha-cell-tumors_27577_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Essential features",
    "url": "https://www.pathologyoutlines.com/topic/pancreasglucagonoma.html#essentialfeatures268956",
    "clean_content": "Essential features\n\n* WHO recognized diagnosis* Produces glucagon, akin to alpha cells of the pancreas* Clinical glucagonoma symptoms include necrolytic migratory erythema, diabetes, weight loss and anemia"
  },
  {
    "id": "glucagonoma-alpha-cell-tumors_27577_1750166973.txt-3",
    "source_document": "glucagonoma-alpha-cell-tumors_27577_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Terminology",
    "url": "https://www.pathologyoutlines.com/topic/pancreasglucagonoma.html#terminology268957",
    "clean_content": "Terminology\n\n* Necrolytic migratory erythema: skin rash of legs, perineum, groin; rash becomes blisters with central clearing, heals with hyperpigmentation but without scarring in 7 - 14 days ([Am J Surg Pathol 1986;10:445](3014912))"
  },
  {
    "id": "glucagonoma-alpha-cell-tumors_27577_1750166973.txt-4",
    "source_document": "glucagonoma-alpha-cell-tumors_27577_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "ICD coding",
    "url": "https://www.pathologyoutlines.com/topic/pancreasglucagonoma.html#icdcoding268958",
    "clean_content": "ICD coding\n\n* ICD-10: [D37.8](https://www.icd10data.com/ICD10CM/Codes/C00-D49/D37-D48/D37-/D37.8) - Neoplasm of uncertain behavior of pancreas"
  },
  {
    "id": "glucagonoma-alpha-cell-tumors_27577_1750166973.txt-5",
    "source_document": "glucagonoma-alpha-cell-tumors_27577_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Epidemiology",
    "url": "https://www.pathologyoutlines.com/topic/pancreasglucagonoma.html#epidemiology268959",
    "clean_content": "Epidemiology\n\n* Incidence rate of approximately 2.5/100,000,000 ([Oncol Lett 2018;15:2749](29435000))* Mean age 54 years* More common in women"
  },
  {
    "id": "glucagonoma-alpha-cell-tumors_27577_1750166973.txt-6",
    "source_document": "glucagonoma-alpha-cell-tumors_27577_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Sites",
    "url": "https://www.pathologyoutlines.com/topic/pancreasglucagonoma.html#sites268960",
    "clean_content": "Sites\n\n* More common in tail of pancreas"
  },
  {
    "id": "glucagonoma-alpha-cell-tumors_27577_1750166973.txt-7",
    "source_document": "glucagonoma-alpha-cell-tumors_27577_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Pathophysiology",
    "url": "https://www.pathologyoutlines.com/topic/pancreasglucagonoma.html#pathophysiology268961",
    "clean_content": "Pathophysiology\n\n* Generally sporadic* Patients with [multiple endocrine neoplasia type 1](https://www.pathologyoutlines.com/topic/pancreasMEN1.html) may have multiple small glucagonomas (with better prognosis)"
  },
  {
    "id": "glucagonoma-alpha-cell-tumors_27577_1750166973.txt-8",
    "source_document": "glucagonoma-alpha-cell-tumors_27577_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Clinical features",
    "url": "https://www.pathologyoutlines.com/topic/pancreasglucagonoma.html#clinicalfeatures268962",
    "clean_content": "Clinical features\n\n* Causes glucagonoma syndrome (necrolytic migratory erythema, diabetes mellitus, weight loss, anemia, angular stomatitis)* Necrolytic migratory erythema may become infected* Roughly half of cases metastasize, often to liver"
  },
  {
    "id": "glucagonoma-alpha-cell-tumors_27577_1750166973.txt-9",
    "source_document": "glucagonoma-alpha-cell-tumors_27577_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Diagnosis",
    "url": "https://www.pathologyoutlines.com/topic/pancreasglucagonoma.html#diagnosis268963",
    "clean_content": "Diagnosis\n\n* Determined clinically, not by immunohistochemical positivity for glucagon"
  },
  {
    "id": "glucagonoma-alpha-cell-tumors_27577_1750166973.txt-10",
    "source_document": "glucagonoma-alpha-cell-tumors_27577_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Laboratory",
    "url": "https://www.pathologyoutlines.com/topic/pancreasglucagonoma.html#laboratory268964",
    "clean_content": "Laboratory\n\n* Elevated blood glucagon levels"
  },
  {
    "id": "glucagonoma-alpha-cell-tumors_27577_1750166973.txt-11",
    "source_document": "glucagonoma-alpha-cell-tumors_27577_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Radiology description",
    "url": "https://www.pathologyoutlines.com/topic/pancreasglucagonoma.html#radiologydescription268965",
    "clean_content": "Radiology description\n\n* MRI: low signal intensity on T1, slightly high signal intensity on T2"
  },
  {
    "id": "glucagonoma-alpha-cell-tumors_27577_1750166973.txt-12",
    "source_document": "glucagonoma-alpha-cell-tumors_27577_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Radiology images",
    "url": "https://www.pathologyoutlines.com/topic/pancreasglucagonoma.html#radiologyimages268966",
    "clean_content": "Radiology images\n\nImages hosted on other servers:  \n\n[![Missing Image](https://www.pathologyoutlines.com/thumb/pancreasglucagonomaradio1.jpg)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356379/figure/f1-ol-09-04-1579/)\n\nCT\n\n[![Missing Image](https://www.pathologyoutlines.com/thumb/pancreasglucagonomaradio2.jpg)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356379/figure/f2-ol-09-04-1579/)\n\nMRI\n\n[![Missing Image](https://www.pathologyoutlines.com/thumb/pancreasglucagonomaradio3.jpg)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2994425/figure/F2/)\n\nLiver metastases"
  },
  {
    "id": "glucagonoma-alpha-cell-tumors_27577_1750166973.txt-13",
    "source_document": "glucagonoma-alpha-cell-tumors_27577_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Case reports",
    "url": "https://www.pathologyoutlines.com/topic/pancreasglucagonoma.html#casereports268967",
    "clean_content": "Case reports\n\n* 50 year old woman with pruritic rash ([Oncol Lett 2015;10:1113](26622635))* 51 year old woman with heart failure ([Endocrinol Diabetes Metab Case Rep 2014;2014:140061](25520848))* 62 year old woman with ovarian mass and history of glucagonoma ([JOP 2013;14:510](24018597))* 64 year old woman with erythematous rash ([Case Rep Surg 2016;2016:1484089](26981306))* 68 year old man with anemia and diabetes ([J Hepatobiliary Pancreat Surg 2003;10:101](12918465))"
  },
  {
    "id": "glucagonoma-alpha-cell-tumors_27577_1750166973.txt-14",
    "source_document": "glucagonoma-alpha-cell-tumors_27577_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Treatment",
    "url": "https://www.pathologyoutlines.com/topic/pancreasglucagonoma.html#treatment268968",
    "clean_content": "Treatment\n\n* Surgery is only curative option* Somatostatin analogues may relieve symptoms ([Clin Endocrinol (Oxf) 2011;74:593](21470282))"
  },
  {
    "id": "glucagonoma-alpha-cell-tumors_27577_1750166973.txt-15",
    "source_document": "glucagonoma-alpha-cell-tumors_27577_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Clinical images",
    "url": "https://www.pathologyoutlines.com/topic/pancreasglucagonoma.html#clinicalimages268969",
    "clean_content": "Clinical images\n\nAFIP images  \n\n[![](https://www.pathologyoutlines.com/imgau/pancreasglucagonomaclinicalAFIP1.jpg)](https://www.pathologyoutlines.com/imgau/pancreasglucagonomaclinicalAFIP1.jpg)\n\nNecrolytic migratory erythema\n\n  \n  \nImages hosted on other servers:  \n\n[![Missing Image](https://www.pathologyoutlines.com/thumb/pancreasglucagonomanejm1.jpeg)](https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/2017/nejm_2017.376.issue-10/nejmicm1603135/20180122/images/img_large/nejmicm1603135_f1.jpeg)\n \n[![](https://www.pathologyoutlines.com/thumb/pancreasglucagonomaclinical2.jpg)](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2994425/figure/F1/)\n\nNecrolytic migratory erythema"
  },
  {
    "id": "glucagonoma-alpha-cell-tumors_27577_1750166973.txt-16",
    "source_document": "glucagonoma-alpha-cell-tumors_27577_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Gross description",
    "url": "https://www.pathologyoutlines.com/topic/pancreasglucagonoma.html#grossdescription268970",
    "clean_content": "Gross description\n\n* Average gross tumor size is 5.0 cm"
  },
  {
    "id": "glucagonoma-alpha-cell-tumors_27577_1750166973.txt-17",
    "source_document": "glucagonoma-alpha-cell-tumors_27577_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Microscopic (histologic) description",
    "url": "https://www.pathologyoutlines.com/topic/pancreasglucagonoma.html#microscopichistologicdescription268971",
    "clean_content": "Microscopic (histologic) description\n\n* Nests of monotonous low grade neuroendocrine cells with salt and pepper nuclei and ample amphophilic cytoplasm"
  },
  {
    "id": "glucagonoma-alpha-cell-tumors_27577_1750166973.txt-18",
    "source_document": "glucagonoma-alpha-cell-tumors_27577_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Microscopic (histologic) images",
    "url": "https://www.pathologyoutlines.com/topic/pancreasglucagonoma.html#microscopichistologicimages268972",
    "clean_content": "Microscopic (histologic) images\n\nImages hosted on other servers:  \n\n[![Missing Image](https://www.pathologyoutlines.com/thumb/pancreasglucagonomamicro1.jpg)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356379/figure/f4-ol-09-04-1579/)\n\nH&E and immunostains\n\n[![](https://www.pathologyoutlines.com/thumb/pancreasglucagonomamicro2.jpg)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3171381/figure/F2/)\n\nH&E and glucagon\n\n[![Missing Image](https://www.pathologyoutlines.com/thumb/pancreasglucagonomamicro3.jpg)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5815774/figure/F2/)\n\nLiver metastasis\n\n[![](https://www.pathologyoutlines.com/thumb/pancreasglucagonomamicro4.jpg)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2994425/figure/F3/)\n\nChromogranin"
  },
  {
    "id": "glucagonoma-alpha-cell-tumors_27577_1750166973.txt-19",
    "source_document": "glucagonoma-alpha-cell-tumors_27577_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Positive stains",
    "url": "https://www.pathologyoutlines.com/topic/pancreasglucagonoma.html#positivestains268973",
    "clean_content": "Positive stains\n\n* **Glucagon** (though this does not establish the diagnosis)* [Synaptophysin](https://www.pathologyoutlines.com/topic/stainssynaptophysin.html) and [chromogranin](https://www.pathologyoutlines.com/topic/stainschromogranin.html)"
  },
  {
    "id": "glucagonoma-alpha-cell-tumors_27577_1750166973.txt-20",
    "source_document": "glucagonoma-alpha-cell-tumors_27577_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Electron microscopy description",
    "url": "https://www.pathologyoutlines.com/topic/pancreasglucagonoma.html#electronmicroscopydescription268974",
    "clean_content": "Electron microscopy description\n\n* Single type secretory granules similar to normal alpha cell granules ([Ultrastruct Pathol 1989;13:15](2537546))"
  },
  {
    "id": "glucagonoma-alpha-cell-tumors_27577_1750166973.txt-21",
    "source_document": "glucagonoma-alpha-cell-tumors_27577_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Sample pathology report",
    "url": "https://www.pathologyoutlines.com/topic/pancreasglucagonoma.html#samplepathologyreport268975",
    "clean_content": "Sample pathology report\n\n* Pancreas and duodenum, Whipple procedure:\n  + Pancreatic neuroendocrine tumor, WHO grade 1 (see synoptic report and comment)+ Comment: The patient’s clinical history of necrolytic migratory erythema is noted. This may be due to glucagon secretion by this tumor, which would make it a glucagonoma. Immunohistochemical stains for synaptophysin and chromogranin are positive and the Ki67 index is approximately 1.2%."
  },
  {
    "id": "glucagonoma-alpha-cell-tumors_27577_1750166973.txt-22",
    "source_document": "glucagonoma-alpha-cell-tumors_27577_1750166973.txt",
    "parent": "pancreas_87",
    "parent_url": "",
    "topic": "Differential diagnosis",
    "url": "https://www.pathologyoutlines.com/topic/pancreasglucagonoma.html#differentialdiagnosis268976",
    "clean_content": "Differential diagnosis\n\n* **Nonglucagon secreting** [pancreatic neuroendocrine tumor](https://www.pathologyoutlines.com/topic/pancreaspen.html):\n  + Must be determined on clinical grounds ([Proc (Bayl Univ Med Cent) 2015;28:46](25552797))"
  }
]